Růžičková O et al. Adv Ther 2018. doi: 10.1007/s12325-018-0779-9

Wong EKC, Papaioannou A. Curr Treat Options in Rheum 2018; Advance online publication. doi: 10.1007/s40674-018-0098-y

The authors provide an overview of the new drugs on the horizon, abaloparatide and romosozumab, which stimulate bone formation, and therefore improve bone mass, structure, and ultimately skeletal strength.2 Minisola S, Cipriani C, Occhiuto M, Pepe J. Intern Emerg Med 2017. doi:10.1007/s11739-017-1719-4

This retrospective analysis found that denosumab significantly improved trabecular bone score independently of bone mineral density in postmenopausal women with osteoporosis. McClung MR, Lippuner K, Brandi ML et al. Osteoporos Int 2017. doi:10.1007/s00198-017-4140-y

This review summarizes the evidence on using of osteoporosis drugs in combination and, with the exception of adding teriparatide to denosumab, finds little data to support using more than one drug at a time. McClung MR. Curr Osteoporos Rep 2017;15:343–352. doi:10.1007/s11914-017-0376-x

This chapter summarizes recent updates in the development of anti-osteoporotic agents, focusing on approaches based on the application of inorganic polymers and combination therapy. Müller WEG, Schröder HC, Wang X. In: Blue Biotechnology . Edited by Müller WEG, Schröder HC, Wang X. Springer International Publishing AG, 2017. doi:10.1007/978-3-319-51284-6_6

An expert summary of available therapies and those on the horizon for patients with osteoporosis including vitamin D, bisphosphonates, selective estrogen receptor modulators, denosumab, and teriparatide. Wong EK-C, Kim LH-Y, Papaioannou A. In: Osteoporosis in Older Persons . Edited by Duque G, Kile DP. Springer International Publishing Switzerland, 2016. doi:10.1007/978-3-319-25976-5_12

An expert review of the manifestations of osteoporosis in childhood, recommendations for monitoring and prevention, and suggestions for when a child should be considered a candidate for therapy. Ward LM, Konji VN, & Ma J. Osteoporos Int 2016;27:2147–2179. doi:10.1007/s00198-016-3515-9

The authors assessed the efficacy of approved osteoporosis pharmacotherapies in preventing fracture and determined that teriparatide, risedronate, and etidronate led to a decreased vertebral fracture risk. Amiche MA et al. Osteoporos Int 2016;27:1989–1998. doi:10.1007/s00198-015-3476-4

Doung et al. explore the potential advances of the inhibition of cathepsin K by odanacatib and determine whether it could be a novel mechanism of action for the treatment of osteoporosis. Duong LT, Leung AT, & Langdahl B. Calcif Tissue Int 2016;98:381–397. doi:10.1007/s00223-015-0051-0